Bristol Myers Squibb Co (BMY) stock
BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 14/3030% below fair value
$61.35−1.58 (-2.51%)
Close on Nov 17, 2026Market cap $125.41BP/E 13.6Yield 4.06%
Bristol Myers Squibb total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Bristol Myers Squibb's total debt was $42.88B at Sep 30, 2026. For fiscal 2025 it was $45.11B, down 9.1% from the year before. Over ten years it grew 21.0% a year on average. The highest annual figure on record is $50.68B in fiscal 2020.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.11B | -9.1% |
| FY2024 | Dec 31, 2024 | $49.65B | +24.8% |
| FY2023 | Dec 31, 2023 | $39.77B | +1.1% |
| FY2022 | Dec 31, 2022 | $39.32B | -11.7% |
| FY2021 | Dec 31, 2021 | $44.55B | -12.1% |
| FY2020 | Dec 31, 2020 | $50.68B | +8.4% |
| FY2019 | Dec 31, 2019 | $46.73B | +535.9% |
| FY2018 | Dec 31, 2018 | $7.35B | -7.7% |
| FY2017 | Dec 31, 2017 | $7.96B | +18.7% |
| FY2016 | Dec 31, 2016 | $6.71B | +0.3% |
| FY2015 | Dec 31, 2015 | $6.69B | -14.6% |
| FY2014 | Dec 31, 2014 | $7.83B | -6.1% |
| FY2013 | Dec 31, 2013 | $8.34B | +12.8% |
| FY2012 | Dec 31, 2012 | $7.39B | +34.7% |
| FY2011 | Dec 31, 2011 | $5.49B | +0.8% |
| FY2010 | Dec 31, 2010 | $5.45B | -14.4% |
| FY2009 | Dec 31, 2009 | $6.36B | -5.6% |
| FY2008 | Dec 31, 2008 | $6.74B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $42.88B | -12.5% |
| Q2 FY2026 | Jun 30, 2026 | $43.12B | -12.3% |
| Q1 FY2026 | Mar 31, 2026 | $44.46B | -10.6% |
| Q4 FY2025 | Dec 31, 2025 | $45.11B | -9.1% |
| Q3 FY2025 | Sep 30, 2025 | $48.98B | -1.6% |
| Q2 FY2025 | Jun 30, 2025 | $49.19B | -6.1% |
| Q1 FY2025 | Mar 31, 2025 | $49.71B | -10.7% |
| Q4 FY2024 | Dec 31, 2024 | $49.65B | +24.8% |
| Q3 FY2024 | Sep 30, 2024 | $49.75B | +32.3% |
| Q2 FY2024 | Jun 30, 2024 | $52.39B | +39.1% |
| Q1 FY2024 | Mar 31, 2024 | $55.68B | +47.2% |
| Q4 FY2023 | Dec 31, 2023 | $39.77B | +1.1% |
| Q3 FY2023 | Sep 30, 2023 | $37.60B | -3.8% |
| Q2 FY2023 | Jun 30, 2023 | $37.68B | -10.4% |
| Q1 FY2023 | Mar 31, 2023 | $37.83B | -15.9% |
| Q4 FY2022 | Dec 31, 2022 | $39.32B | -11.7% |
| Q3 FY2022 | Sep 30, 2022 | $39.10B | -12.6% |
| Q2 FY2022 | Jun 30, 2022 | $42.06B | -6.9% |
| Q1 FY2022 | Mar 31, 2022 | $44.97B | -2.8% |
| Q4 FY2021 | Dec 31, 2021 | $44.55B | -12.1% |
| Q3 FY2021 | Sep 30, 2021 | $44.74B | -0.5% |
| Q2 FY2021 | Jun 30, 2021 | $45.16B | -3.2% |
| Q1 FY2021 | Mar 31, 2021 | $46.28B | -0.9% |
| Q4 FY2020 | Dec 31, 2020 | $50.68B | +8.4% |
| Q3 FY2020 | Sep 30, 2020 | $44.95B | +80.1% |
| Q2 FY2020 | Jun 30, 2020 | $46.67B | +86.9% |
| Q1 FY2020 | Mar 31, 2020 | $46.71B | +676.4% |
| Q4 FY2019 | Dec 31, 2019 | $46.73B | +535.9% |
| Q3 FY2019 | Sep 30, 2019 | $24.96B | +241.6% |
| Q2 FY2019 | Jun 30, 2019 | $24.98B | +238.1% |
| Q1 FY2019 | Mar 31, 2019 | $6.02B | -21.9% |
| Q4 FY2018 | Dec 31, 2018 | $7.35B | -7.7% |
| Q3 FY2018 | Sep 30, 2018 | $7.31B | -13.5% |
| Q2 FY2018 | Jun 30, 2018 | $7.39B | -10.1% |
| Q1 FY2018 | Mar 31, 2018 | $7.70B | -8.7% |
| Q4 FY2017 | Dec 31, 2017 | $7.96B | +18.7% |
| Q3 FY2017 | Sep 30, 2017 | $8.44B | – |
| Q2 FY2017 | Jun 30, 2017 | $8.22B | – |
| Q1 FY2017 | Mar 31, 2017 | $8.43B | – |
| Q4 FY2016 | Dec 31, 2016 | $6.71B | – |
See a number that looks wrong?